Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
InMed Pharmaceuticals Inc. - Common Shares
(NQ:
INM
)
1.520
-0.070 (-4.40%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Jul 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about InMed Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
Next >
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding
November 16, 2022
From
InMed Pharmaceuticals Inc.
Via
GlobeNewswire
TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2023 Financial Report, Corporate Update
November 14, 2022
Via
Investor Brand Network
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
November 11, 2022
From
InMed Pharmaceuticals Inc.
Via
GlobeNewswire
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at ‘Exploring the Neuroprotective Qualities of Rare Cannabinoids’ Webinar Event
November 10, 2022
Via
Investor Brand Network
Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022
November 10, 2022
Meet with InMed’s President and CEO Eric A. Adams and Eric Hsu, SVP of Preclinical Research and Development
From
InMed Pharmaceuticals Inc.
Via
GlobeNewswire
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Support of EB Awareness Week
October 26, 2022
Via
Investor Brand Network
InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week
October 26, 2022
From
InMed Pharmaceuticals Inc.
Via
GlobeNewswire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces 2022 Financial Results, Business Update
September 23, 2022
Via
Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces 2022 Financial Results, Business Update
September 23, 2022
Via
CannabisNewsWire
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Release FY 2022 Financial Report, Corporate Update
September 20, 2022
Via
Investor Brand Network
TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $6M Private Placement Agreement
September 14, 2022
Via
Investor Brand Network
Topics
Intellectual Property
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters into $6M Securities Purchase Agreement
September 12, 2022
Via
Investor Brand Network
Topics
Intellectual Property
InMed Pharmaceuticals Inc. (NASDAQ: INM) Shares Record Huge Gains in Monday Morning Trading
September 12, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Update on Company Objectives and Programs
September 09, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Board Appointment, Changes
August 09, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on Phase 2 EB Trial
July 25, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Michael Woudenberg as Chief Operating Officer
July 18, 2022
Via
Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Results of Peer-Reviewed Study Published in International Journal
June 14, 2022
Via
Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Results of Peer-Reviewed Study Published in International Journal
June 14, 2022
Via
CannabisNewsWire
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Portfolio of Rare Cannabinoids with Launch of d9-THCV
June 09, 2022
Via
Investor Brand Network
Topics
Economy
Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings
June 07, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings
June 07, 2022
Via
Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces $5M Registered Direct and Private Placement Offerings
June 02, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces $5M Registered Direct and Private Placement Offerings
June 02, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 Fiscal 2022 Financial Results, Provides Business Update
May 13, 2022
Via
Investor Brand Network
Topics
Economy
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging Advantage in Rare Cannabinoid Biosynthesis Space
May 09, 2022
Via
Investor Brand Network
Topics
Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging Advantage in Rare Cannabinoid Biosynthesis Space
May 09, 2022
Via
CannabisNewsWire
Topics
Supply Chain
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Participate in Groundbreaking Study with Trokie and Radicle Science
May 05, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Transition from Pure-Play Pharma R&D Firm Featured in Research Report
May 04, 2022
Via
Investor Brand Network
InMed Pharmaceuticals (INM): Notable Launches of High-Value Rare Cannabinoids
May 03, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Edison Investment Research Limited
Via
AccessWire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.